J Miranda1,2, S Triunfo1,2, M Rodriguez-Lopez1,2, M Sairanen3, H Kouru3, M Parra-Saavedra1,2,4, F Crovetto1,2, F Figueras1,2, F Crispi1,2, E Gratacós1,2. 1. BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Deu, IDIBAPS, University of Barcelona, Barcelona, Spain. 2. Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain. 3. PerkinElmer, Inc., Turku, Finland. 4. Maternal-Fetal Unit, CEDIFETAL, Centro de Diagnostico de Ultrasonido e Imágenes, CEDIUL, Barranquilla, Colombia.
Abstract
OBJECTIVE: To explore the potential value of third-trimester combined screening for the prediction of adverse perinatal outcome (APO) in the general population and among small-for-gestational-age (SGA) fetuses. METHODS: This was a nested case-control study within a prospective cohort of 1590 singleton gestations undergoing third-trimester evaluation (32 + 0 to 36 + 6 weeks' gestation). Maternal baseline characteristics, mean arterial blood pressure, fetoplacental ultrasound and circulating biochemical markers (placental growth factor (PlGF), lipocalin-2, unconjugated estriol and inhibin A) were assessed in all women who subsequently had an APO (n = 148) and in a control group without perinatal complications (n = 902). APO was defined as the occurrence of stillbirth, umbilical artery cord blood pH < 7.15, 5-min Apgar score < 7 or emergency operative delivery for fetal distress. Logistic regression models were developed for the prediction of APO in the general population and among SGA cases (defined as customized birth weight < 10th centile). RESULTS: The prevalence of APO was 9.3% in the general population and 27.4% among SGA cases. In the general population, a combined screening model including a-priori risk (maternal characteristics), estimated fetal weight (EFW) centile, umbilical artery pulsatility index (UA-PI), estriol and PlGF achieved a detection rate for APO of 26% (area under receiver-operating characteristics curve (AUC), 0.59 (95% CI, 0.54-0.65)), at a 10% false-positive rate (FPR). Among SGA cases, a model including a-priori risk, EFW centile, UA-PI, cerebroplacental ratio, estriol and PlGF predicted 62% of APO (AUC, 0.86 (95% CI, 0.80-0.92)) at a FPR of 10%. CONCLUSIONS: The use of fetal ultrasound and maternal biochemical markers at 32-36 weeks provides a poor prediction of APO in the general population. Although it remains limited, the performance of the screening model is improved when applied to fetuses with suboptimal fetal growth.
OBJECTIVE: To explore the potential value of third-trimester combined screening for the prediction of adverse perinatal outcome (APO) in the general population and among small-for-gestational-age (SGA) fetuses. METHODS: This was a nested case-control study within a prospective cohort of 1590 singleton gestations undergoing third-trimester evaluation (32 + 0 to 36 + 6 weeks' gestation). Maternal baseline characteristics, mean arterial blood pressure, fetoplacental ultrasound and circulating biochemical markers (placental growth factor (PlGF), lipocalin-2, unconjugated estriol and inhibin A) were assessed in all women who subsequently had an APO (n = 148) and in a control group without perinatal complications (n = 902). APO was defined as the occurrence of stillbirth, umbilical artery cord blood pH < 7.15, 5-min Apgar score < 7 or emergency operative delivery for fetal distress. Logistic regression models were developed for the prediction of APO in the general population and among SGA cases (defined as customized birth weight < 10th centile). RESULTS: The prevalence of APO was 9.3% in the general population and 27.4% among SGA cases. In the general population, a combined screening model including a-priori risk (maternal characteristics), estimated fetal weight (EFW) centile, umbilical artery pulsatility index (UA-PI), estriol and PlGF achieved a detection rate for APO of 26% (area under receiver-operating characteristics curve (AUC), 0.59 (95% CI, 0.54-0.65)), at a 10% false-positive rate (FPR). Among SGA cases, a model including a-priori risk, EFW centile, UA-PI, cerebroplacental ratio, estriol and PlGF predicted 62% of APO (AUC, 0.86 (95% CI, 0.80-0.92)) at a FPR of 10%. CONCLUSIONS: The use of fetal ultrasound and maternal biochemical markers at 32-36 weeks provides a poor prediction of APO in the general population. Although it remains limited, the performance of the screening model is improved when applied to fetuses with suboptimal fetal growth.
Authors: Francesca Crovetto; Fàtima Crispi; Rosa Casas; Andrés Martín-Asuero; Roger Borràs; Eduard Vieta; Ramon Estruch; Eduard Gratacós Journal: JAMA Date: 2021-12-07 Impact factor: 157.335
Authors: Joanna Gent; Sian Bullough; Jane Harrold; Richard Jackson; Kerry Woolfall; Lazaros Andronis; Louise Kenny; Christine Cornforth; Alexander E P Heazell; Emily Benbow; Zarko Alfirevic; Andrew Sharp Journal: Pilot Feasibility Stud Date: 2020-11-19
Authors: So Hyun Shim; Haeng Jun Jeon; Hye Jin Ryu; So Hyun Kim; Seung Gi Min; Min Kyu Kang; Hee Jin Park; Dong Hyun Cha Journal: Medicine (Baltimore) Date: 2021-02-26 Impact factor: 1.817
Authors: Claudia Weinheimer; Haimei Wang; Jessica M Comstock; Purneet Singh; Zhengming Wang; Brent A Locklear; Kasi L Goodwin; J Alan Maschek; James E Cox; Michelle L Baack; Lisa A Joss-Moore Journal: Reprod Sci Date: 2020-01-06 Impact factor: 3.060